Гиперэкспрессия гена WT1 при злокачественных опухолях системы крови: теоретические и клинические аспекты (обзор литературы)

Н.Н. Мамаев, Я.В. Гудожникова, А.В. Горбунова

НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022

Для переписки: Николай Николаевич Мамаев, д-р мед. наук, профессор, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022; тел.: +(7)911-760-50-86; e-mail: nikmamaev524@gmail.com

Для цитирования: Мамаев Н.Н., Гудожникова Я.В., Горбунова А.В. Гиперэкспрессия гена WT1 при злокачественных опухолях системы крови: теоретические и клинические аспекты (обзор литературы). Клиническая онкогематология. 2016;9(3):257-64.

DOI: 10.21320/2500-2139-2016-9-3-257-264


РЕФЕРАТ

В статье обсуждаются полученные в последние годы данные о феномене гиперэкспрессии гена WT1 у пациентов с острыми лейкозами, миелодиспластическими синдромами, хроническим миелолейкозом, неходжкинскими лимфомами и множественной миеломой. Показана большая перспективность мониторинга уровня экспрессии гена WT1 в посттрансплантационный период и после индукционной химиотерапии. Такой подход может использоваться в диагностике минимальной остаточной болезни и раннем выявлении рецидивов лейкозов, а также для их своевременного и контролируемого лечения. Из других исследовательских направлений представляется перспективным тестирование аутотрансплантата на наличие или отсутствие в нем опухолевых элементов, а также оценка эффективности индукционной терапии у больных из группы повышенного прогностического риска.


Ключевые слова: феномен гиперэкспрессии гена WT1, трансплантация гемопоэтических стволовых клеток, химиотерапия, молекулярный мониторинг лечения.

Получено: 8 февраля 2016 г.

Принято в печать: 30 марта 2016 г.

Читать статью в PDFpdficon


ЛИТЕРАТУРА

  1. Call KM, Glaser T, Ito CI, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor gene locus. Cell. 1990;60(3):509–20. doi: 10.1016/0092-8674(90)90601-a.
  2. Rose EA, Glaser T, Jones C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms’ tumor gene. Cell. 1990;60(3):495–508. doi: 10.1016/0092-8674(90)90600-j.
  3. Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia. 1992;6(5):405–9.
  4. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms’ tumour gene (WT1) in human leukemia. Blood. 1997;88(4):1405–12.
  5. Абдулкадыров К.М., Грицаев С.В., Капустин С.И. и др. Экспрессия гена опухоли Вилмса (WT1) в клетках крови больных миелодиспластическим синдромом. Вопросы онкологии. 2004;50(6):668–71.
    [Abdulkadyrov KM, Gritsaev SV, Kapustin SI, et al. Wilms’ tumor gene (WT1) expression in blood cells of patients with myelodysplastic syndrome. Voprosy oncologii. 2004;50(6):668–71. (In Russ)]
  6. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: The WT1 story. Leukemia. 2007;21(5):868–76. doi: 1038/sj.leu.2404624.
  7. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при миелодиспластических синдромах и клиническое значение гиперэкспрессии гена WT1. Клиническая онкогематология. 2014;7(4):551–63.
    [Mamayev NN, Gorbunova AV, Gindina TL, et al. Allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and clinical significance of WT1 gene overexpression. Klinicheskaya onkogematologiya. 2014;7(4):551–63. (In Russ)]
  8. Мамаев Н.Н., Горбунова А.В., Бархатов И.М. и др. Молекулярный мониторинг течения острых миелоидных лейкозов по уровню экспрессии гена WT1 после аллогенной трансплантации гемопоэтических столовых клеток. Клиническая онкогематология. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320.
    [Mamaev NN, Gorbunova AV, Barkhatov IM, et al. Molecular monitoring of WT1 gene expression level in acute myeloid leukemias after allogeneic hematopoietic stem cell transplantation. Clinical oncohematology. 2015;8(3):309–20. doi: 10.21320/2500-2139-2015-8-3-309-320. (In Russ)]
  9. Israyelyan A, Goldstein L, Tsai W, et al. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(1):26–33. doi: 10.1038/bmt.2014.209.
  10. Iwasaki T, Sugisaki Ch, Nagata K, et al. Wilms’ tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia. Pathol Int. 2007;57(10):645–51. doi: 10.1111/j.1440-2007.02153.x.
  11. Tatsumi N, Hojo N, Yamada O, et al. Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. Oncogene. 2015;35(8):1003–14. doi: 10.1038/onc.2015.154.
  12. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–9.
  13. Drakos E, Rassidakis GZ, Tsioli F, et al. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem. Mol Morphol. 2005;13(2):132–7. doi: 10.1097/01.pai.0000143786.62974.66.
  14. Hatta Y, Takeuchi J, Saitoh T, et al. WT1 expression level and clinical factors in multiple myeloma. J Exp Clin Cancer Res. 2005;24(4):595–9.
  15. Na I-K, Kreuzer K-A, Lupberger J, et al. Quantitative RT-PCR of Wilms tumor gene transcripts(WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res. 2005;29(3):343–5. doi: 10.1016/j.leukres.2004.08.003.
  16. Chiusa L, Francia di Celle P, Campisi P, et al. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica. 2006;91(2):270–1. doi: 10.0000/www.haematologica.org/content/91/2/270.short.
  17. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(8):2794–7. doi: 10.1073/pnas.0510423103.
  18. Cao X, Gu WY, Chen ZX, et al. Bone marrow WT1 gene expression and clinical significance in chronic myelogenous leukemia. Zhonghua Nei Ke Za Zhi. 2007;46(4):277–9.
  19. Otahalova E, Ullmannova-Benson V, Klamova FI, et al. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of imatinib resistance. Neoplasma. 2009;56(5):393–7. doi: 10.4149/neo_2009_05_393.
  20. Heesch S, Goekbuget N, Stroux A, et al. Prognostic implications and expression of the Wilms tumor 1 (WT1) gene in adult T-lymphoblastic leukemia. 2010;95(6):942–9. doi: 10.3324/haematol.2009.016386.
  21. Аксенова Е.В. Стандартизированное исследование экспрессии генов BCR-ABL, PRAME и WT1 у больных хроническим миелолейкозом: Диc. ¼ канд. мед. наук. М., 2011. 138 с.
    [Aksyenova EV. Standartizirovannoe issledovanie expressii genov BCR-ABL, PRAME I WT1 u bolnykh chronicheskim myeloleukosom. (Standardized evaluation of the BCR-ABL, PRAME and WT1 gene expression in patients with chronic myeloid leukemia.) [dissertation] Moscow; 2011. 138 p. (In Russ)]
  22. Гапонова Т.В. Экспрессия опухолеассоциированных генов PRAME, WT1 и XIAP у больных множественной миеломой в процессе интенсивной терапии и аутотрансплантации: Диc. ¼ канд. мед. наук. М., 2011. 141 с.
    [Gaponova TV. Expressia opucholeassocirovannykh genov PRAME, WT1 i XIAP u bolnykh mnozhestvennoi myelomoi v processe intensivnoi therapii I autotransplantacii. (Tumor-associated PRAME, WT1 and XIAP gene expression in patients with multiple myeloma during intensive therapy and autografting.) [dissertation] Moscow; 2011. 141 p. (In Russ)]
  23. Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G. WT1-specific responses in high-risk multiple myeloma patients undergoing allogeneic T-cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. 2012;121(2):308–17. doi: 10.1182/blood-2012-06-435040.
  24. Ujj Z, Buglyo G, Udvardy M, et al. WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia. Pathol Oncol Res. 2013;20(3):565–70. doi: 10.1007/s12253-013-9729-
  25. Inoue K, Ogawa H, Yamagami T, et al. Long–term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;88(6):2267–78.
  26. Kletzel N, Olzewski M, Huang W, et al. Utility of WT1 as a reliable tool for the detection of minimal disease in children with leukemia. Pediatr Dev Pathol. 2002;5(3):269–75. doi: 10.1007/s10024-001-0208-x.
  27. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring residual disease in acute leukemia patients. 2002;16(10):2115–21. doi: 10.1038/sj.leu.2402675.
  28. Cilloni D, Giuseppe S, Gottardi E, et al. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Hematol. 2004;112(1–2):79–84. doi: 10.1159/000077562.
  29. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–201. doi: 10.1200/jco.2009.22.4865.
  30. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RTPCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. 2005;19(8):1416–23. doi: 10.1038/sj.leu.2403809.
  31. Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant. 2011;25(2):308–16. doi: 10.1111/j.1399-0012.2010.01251.x.
  32. Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-transplantation. Leuk Res. 2012;36(4):453–8. doi: 10.1016/j.leukres.2011.09.005.
  33. Kwon M, Martinez-Laperche C, Infante M, et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ Tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell trans-plantation: Correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant. 2012;18(8):1235–42. doi: 10.1016/j.bbmt.2012.01.012.
  34. Polak J, Hajkova H, Haskovec C, et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual disease. 2013;60(1):74–82. doi: 10.4149/neo_2013_011.
  35. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–4. doi: 10.3324/haematol.12165.
  36. Andersson C, Li X, Lorenz F, et al. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol. 2012;21(4):225–33. doi: 10.1097/pdm.0b013e318257ddb9.
  37. Mossallam GI, Hamid TM, Mahmoud HK, et al. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients. Hematology. 2013;18(2):69–73. doi: 10.1179/1607845412Y.0000000048.
  38. Ujj Z, Buglyo G, Udvardy M, et al. WT1 expression in adult acute myeloid leukemia: Assessing its presence, magnitude and temporal changes as prognostic factors. Pathol Oncol Res. 2015;22(1):217–21. doi: 10.1007/s12253-015-0002-
  39. Rein LAM, Chao NJ. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. Expert Opin Invest Drugs. 2014;23(3):417–26. doi: 10.1517/13543784.2014.889114.
  40. Paschka P, Marcucci G, Ruppert A.S, et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(28):4595–602. doi: 10.1200/jco.2007.15.2058.
  41. Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377–87. doi: 10.1093/jjco/hyp194.
  42. Vidovic K, Svensson T, Nilsson B, et al. Wilms’ tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia. 2010;24(5):9982–1000. doi: 10.1038/leu.2010.33.
  43. Essafi A, Webb A, Berry RL, et al. A WT1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. Dev Cell. 2011;21(3):559–74. doi: 10.1016/j.devcel.2011.07.014.
  44. Huff V. Wilms’ tumours: about tumour suppressor genes, an oncogene and chameleon gene. Nat Rev Cancer. 2001;11(2):111–21. doi: 10.1038/nrc3002.
  45. Morrison AA, Viney RL, Landomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta. 2008;1785(1):55–62. doi: 10.1016/j.bbcan.2007.10.002.
  46. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukemias. Hematol Onc 2010;28(1):13–9. doi: 10.1002/hon.931.
  47. Haber DA, Sohn RL, Buckler AJ, et al. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA. 1991;88(21):9618–22. doi: 10.1073/pnas.88.21.9618.
  48. Keilholz U, Menssen HD, Gaiger A, et al. Wilms’ tumor gene 1(WT1) in human neoplasia. 2005;19(8):1318–23. doi: 10.1038/sj.leu.2403817.
  49. Hosen N, Shirakata T, Nishida S, et al. The Wilms’ tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia. 2007;21(8):1783–91. doi: 10.1038/sj.leu.2404752.
  50. Miller-Hodges E, Hohenstein P. WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol. 2012;226(2):229–40. doi: 10.1002/path.2977.
  51. Cunningham TJ, Palumbo I, Grosso M, et al. WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. Blood. 2013;122(2):188–92. doi: 10.1182/blood-2012-11-466086.
  52. Patmasirivat P, Fraizer G, Kantarjian H, Saunders GF. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia. 1999;13(6):891–900. doi: 10.1038/sj.leu.2401414.
  53. Gaiger A, Linnerth B, Mann G, et al. Wilms’ tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukemia treated by an intensive chemotherapy protocol. Eur J Haematol. 2009;63(2):86–93. doi: 10.1111/j.1600-0609.1999.tb01121.x.
  54. Arlyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant hematopoiesis. Expert Rev Mol Med. 2007;9(14):1–17. doi: 10.1017/s1462399407000336.
  55. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20(8):1897–909. doi: 10.1093/emboj/20.8.1897.
  56. Scharnhorst V, van den Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273(2):141–61. doi: 10.1016/s0378-1119(01)00593-5.
  57. Baird PN, Simmons PJ. Expression of the Wllms’ tumor gene (WT1) in normal hematopoiesis. Eur Haematol. 1997;25(4):312–20.
  58. Lange T, Hubmann M, Burkhard R, et al. Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. 2011;25(3):498–505. doi: 10.1038/leu.2010.283.
  59. Schmid D, Heinze G, Linnert B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia. 1997;11(5):639–43. doi: 10.1038/sj.leu.2400620.
  60. Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms’ Tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PLoS One. 2014;9(3):e92470. doi: 10.1371/journal.pone.0092470.
  61. Wochlecke C, Wittig S, Arndt C, Gruhn B. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases. J Cancer Res Clin. Oncol. 2014;141(3):523–9. doi: 10.1007/s00432-014-1832-y.
  62. Zhao X-S, Jin S, Zhu H-H, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;47(4):499–507. doi: 10.1038/bmt.2011.121.
  63. Nomdedeu JF, Hoyos M, Carricondo M, et al. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia. 2013;27(11):2157–64. doi: 10.1038/leu.2013.111.
  64. Alonso-Domingues JM, Tenorio M, Velasco D, et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet. 2012;205(4):190–1. doi: 10.1016/j.cancergen.2012.02.008.
  65. Tamaki H, Ogawa H, Inoue K, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood. 1996;88(11):4396–8.
  66. Frairia C, Aydin S, Riera L, et al. WT1 expression in аcute myeloid leukaemia: a useful marker for improving therapy response evaluation. 2013;122(21):2588 (abstract).
  67. Willasch AM, Gruhn B, Coliva T, et al. Standartization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. 2009;23(8):1472–9. doi: 10.1038/leu.2009.51.
  68. Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507–15. doi: 10.1200/jco.2005.03.5303.
  69. Liu J, Wang Yu, Xu L-P, et al. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia-rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(7):929–36. doi: 10.1016/j.bbmt.2014.03.008.
  70. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698–704. doi: 10.1182/blood-2002-06-
  71. Yoon JH, Kim HJ, Shin SH, et al. BAALC and WT1 expression from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol. 2013;91(2):112–21. doi: 10.1111/ejh.12142.
  72. Yoon JH, Kim H-J, Kim J-W, et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. Bone Marrow Transplant. 2014;49(12):1466–74. doi: 10.1038/bmt.2014.180.
  73. Miyagi T, Ahuja H, Kudota T, et al. Expression of the candidate Wilms’ tumor gene, WT1, in human leukemia cells. Leukemia. 1993;7(7):970–7.
  74. Miyawaki S, Hatsumi N, Tamaki T, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma. 2010;51(10):1855–61. doi: 10.3109/10428194.2010.507829.
  75. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat. 1997;9(3):209–25. doi: 10.1002/(sici)1098-1004(1997)9:3<209::aid-humu2>3.0.co;2-2.
  76. Mori N, Okada M, Motoji T, et al. Mutation of the WT1 gene in myelodysplastic syndrome and acute myeloid leukemia post myelodysplastic syndrome. Br J Haematol. 1999;105(3):844–5. doi: 10.1046/j.1365-1999.01497.x.
  77. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28(4):578–85. doi: 10.1200/jco.2009.23.0342.
  78. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222–31. doi: 10.1016/s1040-1741(10)79528-
  79. Shen Y, Zhu Y-M, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593–603. doi: 10.1182/blood-2011-03-
  80. Luo S, Yu K, Yan QX, et al. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2014;56(2):349–57. doi: 10.3109/10428194.2013.791985.
  81. Park SH, Lee HJ, Kim I-S, et al. Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: a multicenter study in Korean population. Ann Lab Med. 2015;35(3):288–97. doi: 10.3343/alm.2015.35.3.288.
  82. Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–55. doi: 10.1016/j.celrep.2014.11.004.
  83. Zhang Q, Zhang Q, Li Q. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance. Int J Lab Hematol. 2015;37(4):e67–71. doi: 10.1111/ijlh.12309.
  84. Brieger J, Weidmann E, Fenchel K, et al. The expression of the Wilms’ tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia. 1994;8(12):2138.
  85. Brieger J, Weidmann E, Maurer U, et al. The Wilms’ tumor gene is frequently expressed in acute myeloblastic leukemia and may provide a marker for residual blast cells detectable by PCR. Ann Oncol. 1995;6(8):811–66.
  86. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90(3):1217–25.
  87. Ogawa H, Ikegame K, Kawakami M, Tamaki H. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma. 2004;45(9):1747–53. doi: 10.1080/10428190410001687503.
  88. Rodrigues PC, Oliveira SN, Vaina MB, et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2007;49(2):133–8. doi: 10.1002/pbc.20953.
  89. Miglino M, Colombo N, Pica C, et al. Wt1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2011;52(10):1961–9. doi: 10.3109/10428194.2011.585673.
  90. Zhao BR, Tang XW, Cen JN, et al. Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia. Zhonghua Yi Xue Za Zhi. 2011;91(20):1375–8.
  91. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia. 1998;12(12):1886–94. doi: 10.1038/sj.leu.2401213.
  92. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004;89(8):926–33.
  93. Yi-ning Y, Xiao-rui W, Chu-xian Z, et al. Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analyse. Ann Hematol. 2015;94(6):929–38. doi: 10.1007/s00277-014-2295-
  94. Nowakowska-Kopera A, Sacha T, Florek I, et al. Wilms’ tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma. 2009;50(8):1326–32. doi: 10.1080/10428190903050021.
  95. Guillaumet-Adkins A, Richter J, Odera MD, et al. Hypermethylation of the alternative AWT1 promotor in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol. 2014;7(1):4. doi: 10.1186/1756-8722-7-4.
  96. Capelli D, Attolico I, Saraceli F, et al Early cumulative incidence of relapse in 80 acute myeloid leukemia patients after chemotherapy and transplant post-consolidation treatment: prognostic role of post-induction WT1. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P287.
  97. Messina C, Candoni A, Carraba MG, et al. Wilms’ tumor gene 1 transcript levels in leukopheresis on peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. Biol Blood Marrow Transpl. 2014;20(10):1586–91. doi: 10.1016/j.bbmt.2014.06.017.
  98. Messina C, Sala E, Carrabba M, et al. Early post-allogeneic transplantation WT1 transcript positivity predicts AML relapse. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P239.
  99. Gianfaldoni G, Mannelli F, Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica. 2010;95(5):833–6. doi: 10.3324/haematol.2009.011908.
  100. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Трансплантация гемопоэтических стволовых клеток при остром миелоидном лейкозе с транслокацией t(8;21)(q22;q22). Клиническая онкогематология. 2013;6(4):439–44.
    [Mamayev NN, Gorbunova AV, Gindina TL, et al. Hemopoietic stem cell transplantation in AML patients with t(8;21)(q22;q22) translocation. Klinicheskaya onkogematologiya. 2013;6(4):439–44. (In Russ)]
  101. Мамаев Н.Н., Горбунова А.В., Гиндина Т.Л. и др. Стойкое восстановление донорского гемопоэза у больной с посттрансплантационным рецидивом острого миеломонобластного лейкоза с inv(3)(q21q26), моносомией 7 и экспрессией онкогена EVI1 после трансфузий донорских лимфоцитов и использования гипометилирующих агентов. Клиническая онкогематология. 2014;7(1):71–5.
    [Mamayev NN, Gorbunova AV, Gindina TL, et al. Stable donor hematopoiesis reconstitution after post-transplantation relapse of acute myeloid leukemia in patient with inv(3)(q21q26), –7 and EVI1 oncogene overexpression treated by donor lymphocyte infusions and hypomethylating agents. Klinicheskaya onkogematologiya. 2014;7(1):71–5. (In Russ)]
  102. Barragan E, Pajuelo JC, Ballester S, et al. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta. 2008;395(1–2):120–3. doi: 10.1016/j.cca.2008.05.021.
  103. Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukemia patients – results from a single-centre study. Br J Haematol. 2004;125(5):590–600. doi: 10.1111/j.1365-2004.04952.x.
  104. Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013;92(8):1111–9. doi: 10.1007/s00277-013-1733-
  105. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2009;82(1):61–8. doi: 10.1111/j.1600-2008.01158.x.
  106. Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141(6):782–991. doi: 10.1111/j.1365-2008.07132.x.
  107. Yamauchi T, Negoro E, Lee S, et al. Detectable Wilms’ tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution’s experience. Anticancer Res. 2013;33(8):3335–40.
  108. Woehlecke C, Wittig S, Sanft J, et al. Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism. J Cancer Res Clin Oncol. 2015;141(7):1283–90. doi: 10.1007/s00432-015-1919-
  109. Jin S, Liu DH, Xu LP, et al. The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi. 2008;47(7):578–81.
  110. Rossi G, Minervini MM, Carella AM, et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res. 2012;36(4):401–6. doi: 10.1016/j.leukres.2011.11.020.
  111. Zhao Q, Zhao Q, Li Q, et al. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance. Int J Lab Hematol. 2014;37(4):e67–71. doi: 10.1111/ijlh.12309.
  112. Mear J-B, Salaun V, Dina N, et al. WT1 and flow cytometry minimal residual disease follow-up after allogeneic transplantation in practice. 40th EBMT Meeting; 2014 30 March – 2 April; Milan, Italy; 2014: Abstract P655.
  113. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. 1999;13(3):393–9. doi: 10.1038/sj.leu.2401341.
  114. Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Scoring System score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988–95. doi: 10.1200/jco.2003.10.503.
  115. Bader P, Niemeyer C, Weber G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. Eur J Haematol. 2004;73(1):25–8. doi: 10.1111/j.1600-2004.00260.x.
  116. Tamura H, Dan K, Yokose N, et al. Prognostic significance of WT1 mRNA and antiWT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res. 2010;34(8):986–90. doi: 10.1016/j.leukres.2009.11.029.
  117. Yamauchi T, Matsuda Y, Takai M, et al. Wilms’ tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia. Anticancer Res. 2012;32(10):4479–83.
  118. Qin Y-Z, Zhu H-H, Liu Y-R, et al. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leuk Lymphoma. 2013;54(7):1442–9. doi: 10.3109/10428194.2012.743656.
  119. Ueda Y, Mizutani C, Nannya Y, et al. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma. 2013;54(7):1450–18. doi: 10.3109/10428194.2012.745074.
  120. Minetto P, Guolo F, Clavio M, et al. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndrome. Leuk Res. 2015;39(8):866–73. doi: 10.1016/j.leukres.2015.04.011.
  121. Santamaria C, Ramos F, Puig N, et al. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. Ann Hematol. 2012;91(12):1887–95. doi: 10.1007/s00277-012-1538-
  122. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms’ tumor gene wt1 transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995;9(6):1060–7.
  123. He YZ, Liang Z, Wu MR, et al. Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia. Leuk Res. 2015;39(6):575–81. doi: 10.1016/j.leukres.2015.03.007.
  124. Xu B, Song S, Yip NC, et al. Simultaneous detection of MDR and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology. 2010;15(2):74–80 doi: 10.1179/ 102453310X12583347009937.
  125. Azuma T, Otsuki T, Kuzushima K, et al. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10(21):7402–12. doi: 10.1158/1078-ccr-04-0825.
  126. Hamalainen MM, Kairisto V, Junonen V, et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukemia. Eur J Haematol. 2008;80(3):201–7. doi: 10.1111/j.1600-2007.01009.x.
  127. Wartheim GB, Bagg A. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Drug. 2011;11(4):361–6. doi: 10.1586/erm.11.19.
  128. Lambert J, Lambert J, Niboured O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014;5(15):6280–8. doi: 10.18632/oncotarget.2196.
  129. Steinbach D, Bader P, Willasch A, et al. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myeloid leukemia. Clin Cancer Res. 2014;21(6):1353–9. doi: 10.1158/1078-ccr-14-1999.
  130. Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res. 2012;36(4):453–8. doi: 10.1016/j.leukres.2011.09.005.
  131. Noronha SA, Farrar JE, Alonzo TA, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the children’s oncology group. Pediatr Blood Cancer. 2009;53(6):1136–9. doi: 10.1002/pbc.22142.
  132. Kim HJ, Choi EJ, Sohn HJ, et al. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia. Eur J Haematol. 2013;91(5):411–22. doi: 10.1111/ejh.12167.
  133. Niavarani A, Currie E, Reyal Y, et al. APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts. PloS One. 2015;10(3):e0120089. doi: 10.1371/journal.pone.0120089.
  134. Taira C, Matsuda K, Kamijyo Y, et al. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course. Clin Chim Acta. 2011;412(1–2):53–8. doi: 10.1016/j.cca.2010.09.011.
  135. Morita Y, Heike1 Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer. 2006;119(6):1360–7. doi: 10.1002/ijc.21960.
  136. Tsuboi A, Oka Y, Nakajima H, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86(5):414–7. doi: 10.1007/bf02983998.
  137. Narita M, Masuko M, Kurasaki T, et al. WT1 peptide vaccination in combination with imatinib for a patient with CML in the chronic phase. Int J Med Sci. 2010;7(2):72–81. doi: 10.7150/ijms.7.72.